MISSISSAUGA, Ontario,
June 29, 2018 /PRNewswire/
-- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX:
ARZ) ("Aralez" or the "Company") today announced the results of
the matters voted upon at the Company's 2018 annual meeting (the
"Meeting") of the shareholders of the Company (the "Shareholders")
held earlier today, which included the election of directors, as
described below.
The total number of common shares of the Company ("Common
Shares") represented by Shareholders present in person or
represented by proxy at the Meeting was an aggregate of 48,911,838,
representing 72.79% of the Company's issued and outstanding Common
Shares as of the record date for the Meeting.
According to proxies received and a vote by ballot, the voting
results in respect of each of the following seven director
nominees, all of whom previously served as directors of the
Company, were as follows:
Nominee
|
Number of
Shares
|
Percentage of
Votes Cast
(approximate)
|
|
Votes For:
|
Votes
Withheld:
|
Votes For:
|
Votes
Withheld:
|
Arthur S. Kirsch
(Chairperson)
|
15,225,514
|
2,794,430
|
84.49%
|
15.51%
|
Adrian
Adams
|
15,246,171
|
2,773,773
|
84.61%
|
15.39%
|
Neal F.
Fowler
|
15,270,738
|
2,749,206
|
84.74%
|
15.26%
|
Rob Harris
|
15,953,415
|
2,066,529
|
88.53%
|
11.47%
|
Kenneth B. Lee,
Jr.
|
15,197,622
|
2,822,322
|
84.34%
|
15.66%
|
Seth A. Rudnick,
M.D.
|
15,226,552
|
2,793,392
|
84.50%
|
15.50%
|
F. Martin
Thrasher
|
15,969,193
|
2,050,751
|
88.62%
|
11.38%
|
Each of the other matters bought before the Shareholders for
consideration and approval at the Meeting, as described in the
Company's proxy statement dated May 18,
2018, was duly approved by the requisite number of
votes.
Final voting results of all other matters voted on at the
Meeting will be made available on EDGAR at www.sec.gov and SEDAR at
www.sedar.com.
About Aralez Pharmaceuticals Inc.
Aralez
Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a Canadian
specialty pharmaceutical company focused on delivering meaningful
products to improve patients' lives while creating shareholder
value by acquiring, developing and commercializing products in
various specialty areas. Aralez's Global Headquarters is in
Mississauga, Ontario, Canada and
the Irish Headquarters is in Dublin,
Ireland. More information about Aralez can be found at
www.aralez.com.
Aralez Pharmaceuticals US Inc. Contact:
Christopher Bona
312-329-3918
info@aralez.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/aralez-announces-voting-results-from-2018-annual-meeting-of-shareholders-300674952.html
SOURCE Aralez Pharmaceuticals Inc.